Here are the items covered in the respective PR's concerning their NEW patents:
Reduce the microbial load of an infected diabetic foot ulcer;
• Decrease the recurrence rate of an infected diabetic foot ulcer;
• Decrease the likelihood of dehiscence of an infected diabetic foot ulcer;
• Decrease the likelihood of amputation resulting from an infected diabetic foot ulcer;
• Decrease the likelihood of systemic inflammatory response syndrome from an infected diabetic foot ulcer;
• Decrease the likelihood of sepsis resulting from an infected diabetic foot ulcer.
The only difference is that in December they state they now had 24 patents, and as of today they have 33 patents. These guys pull PRs out of their #$%$ so it must be bigger than Trump's head, because they sure pull a lot of stuff out of it!
Counting patents can be a little tricky. If the European Patent Office grants your patent and you nationalize it into six countries, do you have one patent, six patents or seven patents? (Personally I would count it as one, but it really depends on why you are counting them.)
It is much easier to count how many patents OCLS has covering the actual composition (microcyn/puracyn/vetericyn). That would be NONE.
The main interest I have as an investor is whether their forward looking guidance comes true - which is - they expect to be "consistently profitable" in 2014. If that happens, I'll be a happy investor and all this nitpicking will be irrelevant. It's the bottom line that counts.